There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation ...

By Nikhil Sharma and Pranav Kashyap (Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...

Generics businesses achieve pretty defendable margins, yet their valuations are at material discounts to most of the Big ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...